These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 10804636)

  • 21. Inhibition of VEGF receptor-2 decreases the development of hyperdynamic splanchnic circulation and portal-systemic collateral vessels in portal hypertensive rats.
    Fernandez M; Mejias M; Angermayr B; Garcia-Pagan JC; Rodés J; Bosch J
    J Hepatol; 2005 Jul; 43(1):98-103. PubMed ID: 15893841
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Experimental models of portal hypertension].
    Oberti F; Vuillemin E; Fort J; Calès P
    Gastroenterol Clin Biol; 2000 Oct; 24(10):896-901. PubMed ID: 11084425
    [No Abstract]   [Full Text] [Related]  

  • 23. Comparative study of portal vein embolization versus portal vein ligation for induction of hypertrophy of the future liver remnant using a mini-pig model.
    Wilms C; Mueller L; Lenk C; Wittkugel O; Helmke K; Krupski-Berdien G; Rogiers X; Broering DC
    Ann Surg; 2008 May; 247(5):825-34. PubMed ID: 18438120
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Portal high flow state in dogs].
    Huang YT
    Zhonghua Wai Ke Za Zhi; 1993 Apr; 31(4):195-8. PubMed ID: 8275830
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Extrahepatic portal hypertension in dogs produced with Boerema's instrument for slow ligation.
    Klopper PJ; Klompenhouwer JA
    Arch Chir Neerl; 1967; 19(2):127-38. PubMed ID: 6061287
    [No Abstract]   [Full Text] [Related]  

  • 26. Chronic cyclooxygenase blockade enhances the vasopressin responsiveness in collaterals of portal hypertensive rats.
    Huang HC; Wang SS; Chen YC; Lee FY; Chang FY; Lin HC; Hou MC; Chang CC; Lee SD
    Scand J Gastroenterol; 2006 Dec; 41(12):1440-5. PubMed ID: 17101575
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increased duodenal mucosa infiltration by mast cells in rats with portal hypertension.
    Diez-Arias JA; Aller MA; Palma MD; Arias JL; Muñiz E; Sánchez M; Arias J
    Dig Surg; 2001; 18(1):34-40. PubMed ID: 11244257
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mast cell inhibition by ketotifen reduces splanchnic inflammatory response in a portal hypertension model in rats.
    Sánchez-Patán F; Aller MA; Cuellar C; Rodero M; Corcuera MT; Nava MP; Gómez F; Blanco MD; Guerrero S; Anchuelo R; Muñiz E; Alonso MJ; Teijón JM; Arias J
    Exp Toxicol Pathol; 2008 Aug; 60(4-5):347-55. PubMed ID: 18514499
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vasopressin response and shunting modulation in cirrhotic rats by chronic nitric oxide inhibition.
    Huang HC; Wang SS; Lee FY; Chang CC; Chang FY; Lin HC; Hou MC; Lee SD
    J Gastroenterol Hepatol; 2008 Jul; 23(7 Pt 2):e265-9. PubMed ID: 17764528
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of nitric oxide synthase and cyclooxygenase in hyperdynamic splanchnic circulation of portal hypertension.
    Xu J; Cao H; Liu H; Wu ZY
    Hepatobiliary Pancreat Dis Int; 2008 Oct; 7(5):503-8. PubMed ID: 18842497
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cavo-portal transposition in rat: a new simple model.
    Di Domenico S; Bovio G; Gelli M; Ravazzoni F; Andorno E; Cottalasso D; Valente U
    BMC Surg; 2007 Aug; 7():18. PubMed ID: 17705819
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of thromboxane A2 in early BDL-induced portal hypertension.
    Yokoyama Y; Xu H; Kresge N; Keller S; Sarmadi AH; Baveja R; Clemens MG; Zhang JX
    Am J Physiol Gastrointest Liver Physiol; 2003 Mar; 284(3):G453-60. PubMed ID: 12431905
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Changes in intrahepatic portal systemic shunt flow in a rat model of acute intrahepatic presinusoidal portal hypertension].
    Li XN; Shi Y; Ding W
    Zhonghua Gan Zang Bing Za Zhi; 2005 Apr; 13(4):278-81. PubMed ID: 15850516
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intrahepatic portal vein branches after extrahepatic portal vein occlusion. Experimental study.
    Ferko A; Lesko M; Krajina A; Hulek P; Rösch J; Rabkin J
    Hepatogastroenterology; 2001; 48(38):475-9. PubMed ID: 11379337
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessment of the regularity of hepatic arterio-portal anastomosis exploiting in vivo microscopy.
    Mohamad RA; Murata S; Kumazaki T
    Radiat Med; 2005 Mar; 23(2):85-8. PubMed ID: 15827524
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evolutive phases of experimental prehepatic portal hypertension.
    Aller MA; Nava MP; Cuellar C; Chivato T; Arias JL; Sanchez-Patan F; de Vicente F; Alvarez E; Arias J
    J Gastroenterol Hepatol; 2007 Jul; 22(7):1127-33. PubMed ID: 17608859
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Establishment of a new rat model of portal hypertension by intraportal injection of microspheres].
    Li XA; Wang M; Lu K
    Zhonghua Wai Ke Za Zhi; 1997 Jan; 35(1):52-5. PubMed ID: 10374511
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Restriction of drinking water abrogates splanchnic vasodilation and portal hypertension in portal vein-ligated rats.
    Heinemann A; Schuligoi R; Lippe IT; Stauber RE
    Pharmacology; 2009; 83(1):26-32. PubMed ID: 18987488
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Portal vein arterialization increases hepatocellular apoptosis and inhibits liver regeneration.
    Schleimer K; Stippel DL; Kasper HU; Prenzel K; Gaudig C; Tawadros S; Hoelscher AH; Beckurts KT
    J Surg Res; 2008 Oct; 149(2):250-8. PubMed ID: 18599086
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The microscopical appearance of the subcutaneously transposed spleen.
    Börjesson B; Idvall I
    Ann Chir Gynaecol; 1976; 65(3):220-5. PubMed ID: 962292
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.